Morgan Stanley’s Biostage, Inc. Common Stock BSTG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-10,772
| Closed | -$4K | – | 6852 |
|
|
2017
Q3 | $4K | Sell |
10,772
-1,004
| -9% | -$402 | ﹤0.01% | 6342 |
|
|
2017
Q2 | $4K | Sell |
11,776
-1,855
| -14% | -$589 | ﹤0.01% | 6398 |
|
|
2017
Q1 | $5K | Buy |
13,631
+7,726
| +131% | +$4.23K | ﹤0.01% | 6373 |
|
|
2016
Q4 | $5K | Sell |
5,905
-2,457
| -29% | -$2.19K | ﹤0.01% | 6286 |
|
|
2016
Q3 | $9K | Hold |
8,362
| – | – | ﹤0.01% | 6139 |
|
|
2016
Q2 | $10K | Sell |
8,362
-2,000
| -19% | -$3.23K | ﹤0.01% | 6068 |
|
|
2016
Q1 | $18K | Buy |
10,362
+200
| +2% | +$332 | ﹤0.01% | 5962 |
|
|
2015
Q4 | $22K | Sell |
10,162
-475
| -4% | -$662 | ﹤0.01% | 6009 |
|
|
2015
Q3 | $9K | Sell |
10,637
-712
| -6% | -$807 | ﹤0.01% | 6275 |
|
|
2015
Q2 | $17K | Buy |
11,349
+150
| +1% | +$367 | ﹤0.01% | 6181 |
|
|
2015
Q1 | $37K | Sell |
11,199
-36,142
| -76% | -$123K | ﹤0.01% | 5895 |
|
|
2014
Q4 | $151K | Sell |
47,341
-66,921
| -59% | -$332K | ﹤0.01% | 5372 |
|
|
2014
Q3 | $926K | Sell |
114,262
-55,449
| -33% | -$454K | ﹤0.01% | 4098 |
|
|
2014
Q2 | $1.77M | Buy |
169,711
+69,706
| +70% | +$594K | ﹤0.01% | 3576 |
|
|
2014
Q1 | $907K | Sell |
100,005
-4,123
| -4% | -$24.4K | ﹤0.01% | 4072 |
|
|
2013
Q4 | $494K | Buy |
+104,128
| New | +$487K | ﹤0.01% | 4451 |
|
Morgan Stanley's BSTG Position: Q4 2017 in Review
Morgan Stanley sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2017, closing a stake of 10,772 shares — an estimated $4K sold.
Morgan Stanley first reported a position in BSTG in Q4 2013 and held it in 16 quarters. The position peaked at $1.77M in Q2 2014. 0 funds tracked by Wall St. Rank hold BSTG as of Q4 2017.
- Morgan Stanley reported no remaining Biostage, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
- Morgan Stanley sold 10,772 Biostage, Inc. Common Stock shares in Q4 2017, an estimated $4K.
- Morgan Stanley first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
- Morgan Stanley's Biostage, Inc. Common Stock position peaked at $1.77M in Q2 2014.
- 0 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2017.
Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.